Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8383866 | 0.86 | HCRTR2 (0.38) | HCRTR2EPHX1TDP1MEN1KMT2A | |
| SCHEMBL14432052 | 0.84 | EPHX1 (0.39) | HCRTR2EPHX1TDP1MEN1KMT2A | |
| SCHEMBL7098423 | 0.83 | EPHX1 (0.40) | HCRTR2EPHX1TDP1MEN1KMT2A | |
| SCHEMBL8926365 | 0.83 | HCRTR2 (0.41) | HCRTR2EPHX1TDP1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL22389973 | 0.83 | EPHX1 (0.38) | HCRTR2EPHX1TDP1MEN1KMT2A | |
| SCHEMBL9183637 | 0.81 | IRAK4 (0.32) | TDP1 | |
| SCHEMBL22532010 | 0.81 | HCRTR2 (0.42) | HCRTR2EPHX1TDP1MEN1KMT2A | |
| SCHEMBL9183640 | 0.79 | EPHX2 (0.37) | — | |
| SCHEMBL9181193 | 0.79 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL8925642 | 0.78 | HCRTR2 (0.44) | HCRTR2EPHX1TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7149758-A | — | — | None | — | — | JP | disclosed |
| EP-4486453-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| EP-4058146-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023166103-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CURZA GLOBAL, LLC. | 2023-09-07 | — | — | US | disclosed |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-09 | — | — | US | disclosed |
| EP-4058146-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2022-09-21 | — | — | EP | disclosed |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| CN-113825748-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2021-12-21 | — | — | CN | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ZOETIS WLC LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1255739-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001053273-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-07-26 | — | — | WO | disclosed |
| JP-H07149758-A | INTERMEDIATE FOR PREPARATION OF AZABICYCLO QUINOLONE CARBOXYLIC ACID | PFIZER INC | 1995-06-13 | — | — | JP | disclosed |
| US-5391763-A | 3-aza-bicyclo[3.1.0]hexanes which are intermediates for anti-bacterial azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5266569-A | Azatricyclo carboxylic acids useful as anti-bacterial agents | PFIZER INC. (US) | 1993-11-30 | — | — | US | disclosed |
| US-5229396-A | Anti-bacterial azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5164402-A | Bactericides | PFIZER INC (US) | 1992-11-17 | — | — | US | disclosed |
| WO-1991002526-A1 | AZABICYCLO QUINOLONE CARBOXYLIC ACIDS | PFIZER INC. (US) | 1991-03-07 | — | — | WO | disclosed |
| EP-0413455-A2 | Azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CLPP, RPN2, MPO | HCRTR2 4809/4885EPHX1 4359/4885TDP1 3800/4885 |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ABL1, NQO2, CBR3 | HCRTR2 1943/4885EPHX1 4602/4885TDP1 3071/4885 |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | HCRTR2 2033/4885EPHX1 4016/4885TDP1 3817/4885 |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | HCRTR2 4724/4885EPHX1 4311/4885TDP1 4219/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | HCRTR2 2033/4885EPHX1 4016/4885TDP1 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.